Laddar...
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
In the last 3-5 years strong evidence has been gathered demonstrating ErbB3 as a key node for the progression of several cancer types. From the mechanistic standpoint the intracellular region of this receptor is rich of tyrosine residues that, upon phosphorylation, become high affinity binding sites...
Sparad:
| Huvudupphovsmän: | , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Impact Journals LLC
2012
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3478453/ https://ncbi.nlm.nih.gov/pubmed/22889873 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|